Arama Sonuçları - Dirk Müller‐Wieland

Sonuçları Daraltın
  1. 1
    Obesity Associated with a Mutation in a Genetic Regulator of Adipocyte Differentiation

    Obesity Associated with a Mutation in a Genetic Regulator of Adipocyte Differentiation Yazar: Michael Ristow, Dirk Müller‐Wieland, A. Pfeiffer, Wilhelm Krone, C. Ronald Kahn

    Baskı/Yayın Bilgisi 1998
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  2. 2
    Insulin-activated Erk-mitogen-activated Protein Kinases Phosphorylate Sterol Regulatory Element-binding Protein-2 at Serine Residues 432 and 455 in Vivo

    Insulin-activated Erk-mitogen-activated Protein Kinases Phosphorylate Sterol Regulatory Element-binding Protein-2 at Serine Residues 432 and 455 in Vivo Yazar: Jörg Kotzka, Stefan Lehr, Gunther Roth, Haluk Avci, Birgit Knebel, Dirk Müller‐Wieland

    Baskı/Yayın Bilgisi 2004
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  3. 3
    SREBP-1 Mediates Activation of the Low Density Lipoprotein Receptor Promoter by Insulin and Insulin-like Growth Factor-I

    SREBP-1 Mediates Activation of the Low Density Lipoprotein Receptor Promoter by Insulin and Insulin-like Growth Factor-I Yazar: Rüdiger Streicher, Jörg Kotzka, Dirk Müller‐Wieland, Gerhard Siemeister, Martina Munck, Haluk Avci, Wilhelm Krone

    Baskı/Yayın Bilgisi 1996
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  4. 4
    Five cases with central diabetes insipidus and hypogonadism as first presentation of neurosarcoidosis

    Five cases with central diabetes insipidus and hypogonadism as first presentation of neurosarcoidosis Yazar: Catharina Bullmann, Michael Faust, Anne Lisbeth Hoffmann, Christina Heppner, F. Jockenhövel, Dirk Müller‐Wieland, W Krone

    Baskı/Yayın Bilgisi 2000
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  5. 5
    Definition, Classification and Diagnosis of Diabetes Mellitus

    Definition, Classification and Diagnosis of Diabetes Mellitus Yazar: Astrid Petersmann, Dirk Müller‐Wieland, Ulrich Müller, Ruediger Landgraf, Matthias Nauck, Guido Freckmann, Lutz Heinemann, Erwin Schleicher

    Baskı/Yayın Bilgisi 2014
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  6. 6
    Liver-Specific Expression of Transcriptionally Active SREBP-1c Is Associated with Fatty Liver and Increased Visceral Fat Mass

    Liver-Specific Expression of Transcriptionally Active SREBP-1c Is Associated with Fatty Liver and Increased Visceral Fat Mass Yazar: Birgit Knebel, Jutta Haas, Sonja Hartwig, Sylvia Jacob, Cornelia Köllmer, Ulrike Nitzgen, Dirk Müller‐Wieland, Jörg Kotzka

    Baskı/Yayın Bilgisi 2012
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  7. 7
    Sterol regulatory element binding proteins (SREBP)-1a and SREBP-2 are linked to the MAP-kinase cascade

    Sterol regulatory element binding proteins (SREBP)-1a and SREBP-2 are linked to the MAP-kinase cascade Yazar: Jörg Kotzka, Dirk Müller‐Wieland, Gunther Roth, L. Kremer, Martina Munck, Sandra Schürmann, Birgit Knebel, Wilhelm Krone

    Baskı/Yayın Bilgisi 2000
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  8. 8
    Preventing Phosphorylation of Sterol Regulatory Element-Binding Protein 1a by MAP-Kinases Protects Mice from Fatty Liver and Visceral Obesity

    Preventing Phosphorylation of Sterol Regulatory Element-Binding Protein 1a by MAP-Kinases Protects Mice from Fatty Liver and Visceral Obesity Yazar: Jörg Kotzka, Birgit Knebel, Jutta Haas, L. Kremer, Sylvia Jacob, Sonja Hartwig, Ulrike Nitzgen, Dirk Müller‐Wieland

    Baskı/Yayın Bilgisi 2012
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  9. 9
    Definition, Classification and Diagnosis of Diabetes Mellitus

    Definition, Classification and Diagnosis of Diabetes Mellitus Yazar: Astrid Petersmann, Dirk Müller‐Wieland, Ulrich Müller, Rüdiger Landgraf, Matthias Nauck, Guido Freckmann, Lutz Heinemann, Erwin Schleicher

    Baskı/Yayın Bilgisi 2019
    Tam Metin Erişim Tam Metin Erişim
    Revisão
    Favorilerime ekle
    Kaydedildi:
  10. 10
    MAP Kinases Erk1/2 Phosphorylate Sterol Regulatory Element-binding Protein (SREBP)-1a at Serine 117 in Vitro

    MAP Kinases Erk1/2 Phosphorylate Sterol Regulatory Element-binding Protein (SREBP)-1a at Serine 117 in Vitro Yazar: Gunther Roth, Jörg Kotzka, L. Kremer, Stefan Lehr, Christiane Lohaus, Helmut E. Meyer, Wilhelm Krone, Dirk Müller‐Wieland

    Baskı/Yayın Bilgisi 2000
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  11. 11
    Clinical course of COVID-19 patients needing supplemental oxygen outside the intensive care unit

    Clinical course of COVID-19 patients needing supplemental oxygen outside the intensive care unit Yazar: Ayham Daher, Paul Balfanz, Maria Aetou, Bojan Hartmann, Dirk Müller‐Wieland, Tobias Müller, Nikolaus Marx, Michael Dreher, Christian Cornélissen

    Baskı/Yayın Bilgisi 2021
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  12. 12
    Follow up of patients with severe coronavirus disease 2019 (COVID-19): Pulmonary and extrapulmonary disease sequelae

    Follow up of patients with severe coronavirus disease 2019 (COVID-19): Pulmonary and extrapulmonary disease sequelae Yazar: Ayham Daher, Paul Balfanz, Christian Cornélissen, Annegret Müller, Ingmar Bergs, Nikolaus Marx, Dirk Müller‐Wieland, Bojan Hartmann, Michael Dreher, Tobias Müller

    Baskı/Yayın Bilgisi 2020
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  13. 13
    <scp>L</scp>ow‐density lipoprotein cholesterol and non‐high‐density lipoprotein cholesterol in type 1 diabetes and type 2 diabetes: Lipid goal attainment in a large <scp>German–Austrian</scp> diabetes registry

    <scp>L</scp>ow‐density lipoprotein cholesterol and non‐high‐density lipoprotein cholesterol in type 1 diabetes and type 2 diabetes: Lipid goal attainment in a large <scp>German–Aus... Yazar: Julia Brandts, Sascha R. Tittel, Peter Bramlage, Thomas Danne, Johanna Brix, Stefan Zimny, Christoph H. J. Heyer, Reinhard W. Holl, Dirk Müller‐Wieland

    Baskı/Yayın Bilgisi 2023
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  14. 14
    Efficacy and Safety of Ezetimibe Added to Atorvastatin Versus Atorvastatin Uptitration or Switching to Rosuvastatin in Patients With Primary Hypercholesterolemia

    Efficacy and Safety of Ezetimibe Added to Atorvastatin Versus Atorvastatin Uptitration or Switching to Rosuvastatin in Patients With Primary Hypercholesterolemia Yazar: Harold Bays, Maurizio Averna, Claudio Majul, Dirk Müller‐Wieland, Annamaria De Pellegrin, Hilde Giezek, Raymond Lee, Robert S. Lowe, Philippe Brudi, Joseph Triscari, Michel Farnier

    Baskı/Yayın Bilgisi 2013
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  15. 15
    Therapy of Type 2 Diabetes

    Therapy of Type 2 Diabetes Yazar: Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald Klein, Dirk Müller‐Wieland, Michael A. Nauck, Hans‐Martin Reuter, Erhard Siegel

    Baskı/Yayın Bilgisi 2019
    Tam Metin Erişim
    Revisão
    Favorilerime ekle
    Kaydedildi:
  16. 16
    Phosphorylation of sterol regulatory element-binding protein (SREBP)-1c by p38 kinases, ERK and JNK influences lipid metabolism and the secretome of human liver cell line HepG2

    Phosphorylation of sterol regulatory element-binding protein (SREBP)-1c by p38 kinases, ERK and JNK influences lipid metabolism and the secretome of human liver cell line HepG2 Yazar: Birgit Knebel, Stefan Lehr, Sonja Hartwig, Jutta Haas, Gernot Kaber, Hans-Dieter Dicken, Franciscus Susanto, Lothar Bohne, Sylvia Jacob, Ulrike Nitzgen, Waltraud Paßlack, Dirk Müller‐Wieland, Jörg Kotzka

    Baskı/Yayın Bilgisi 2014
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  17. 17
    Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add‐on to metformin in patients with type 2 diabetes

    Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add‐on to metformin in patients with type 2 diabetes Yazar: Dirk Müller‐Wieland, Monika Kellerer, Katarzyna Cypryk, Dasa Skripova, Katja Rohwedder, Eva Johnsson, Ricardo García‐Sánchez, Raisa Kurlyandskaya, C. David Sjöström, Stephan Jacob, Jochen Seufert, Nalina Dronamraju, Katalin Csomós

    Baskı/Yayın Bilgisi 2018
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  18. 18
    No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies

    No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies Yazar: Helen M. Colhoun, Henry N. Ginsberg, Jennifer G. Robinson, Lawrence A. Leiter, Dirk Müller‐Wieland, Robert R. Henry, Bertrand Cariou, Marie T. Baccara‐Dinet, Robert Pordy, Laurence Merlet, Robert H. Eckel

    Baskı/Yayın Bilgisi 2016
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  19. 19
    Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies

    Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies Yazar: Kausik K. Ray, Stefano Del Prato, Dirk Müller‐Wieland, Bertrand Cariou, Helen M. Colhoun, Francisco J. Tinahones, Catherine Domenger, Alexia Letierce, Jonas Mandel, Rita Samuel, Maja Bujas‐Bobanovic, Lawrence A. Leiter

    Baskı/Yayın Bilgisi 2019
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  20. 20
    Efficacy and safety of alirocumab in insulin‐treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The <scp>ODYSSEY DM‐INSULIN</scp> randomized trial

    Efficacy and safety of alirocumab in insulin‐treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The <scp>ODYSSEY DM‐INSULIN</scp> randomized trial Yazar: Lawrence A. Leiter, Bertrand Cariou, Dirk Müller‐Wieland, Helen M. Colhoun, Stefano Del Prato, Francisco J. Tinahones, Kausik K. Ray, Maja Bujas‐Bobanovic, Catherine Domenger, Jonas Mandel, Rita Samuel, Robert R. Henry

    Baskı/Yayın Bilgisi 2017
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:

Arama Araçları: